These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25921617)

  • 1. Improved parenchymal liver enhancement with extended delay on Gd-EOB-DTPA-enhanced MRI in patients with parenchymal liver disease: associated clinical and imaging factors.
    Esterson YB; Flusberg M; Oh S; Mazzariol F; Rozenblit AM; Chernyak V
    Clin Radiol; 2015 Jul; 70(7):723-9. PubMed ID: 25921617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a predictor of insufficient enhancement during the hepatobiliary phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging.
    Cui E; Long W; Luo L; Hu M; Huang L; Chen X
    Acta Radiol; 2017 Oct; 58(10):1174-1181. PubMed ID: 28090793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA.
    Tamada T; Ito K; Sone T; Yamamoto A; Yoshida K; Kakuba K; Tanimoto D; Higashi H; Yamashita T
    J Magn Reson Imaging; 2009 Mar; 29(3):636-40. PubMed ID: 19243060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limitations of GD-EOB-DTPA-enhanced MRI: can clinical parameters predict suboptimal hepatobiliary phase?
    Kobi M; Paroder V; Flusberg M; Rozenblit AM; Chernyak V
    Clin Radiol; 2017 Jan; 72(1):55-62. PubMed ID: 27842889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests.
    Kukuk GM; Schaefer SG; Fimmers R; Hadizadeh DR; Ezziddin S; Spengler U; Schild HH; Willinek WA
    Eur Radiol; 2014 Oct; 24(10):2482-90. PubMed ID: 25030459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivariable analysis of clinical influence factors on liver enhancement of Gd-EOB-DTPA-enhanced 3T MRI.
    Verloh N; Haimerl M; Zeman F; Teufel A; Lang S; Stroszczynski C; Fellner C; Wiggermann P
    Rofo; 2015 Jan; 187(1):29-35. PubMed ID: 25531338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
    Feuerlein S; Gupta RT; Boll DT; Merkle EM
    Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential clinical factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhanced MR imaging.
    Higaki A; Tamada T; Sone T; Kanki A; Sato T; Tanimoto D; Higashi H; Ito K
    Magn Reson Imaging; 2012 Jun; 30(5):689-93. PubMed ID: 22459437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: Quantitative and qualitative analysis.
    Yeom SK; Byun JH; Kim HJ; Park SH; Kim N; Shin YM; Kim PN
    Magn Reson Imaging; 2013 Jul; 31(6):911-7. PubMed ID: 23598063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
    Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
    Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of liver cirrhosis on liver enhancement at Gd-EOB-DTPA enhanced MRI at 3 Tesla.
    Verloh N; Haimerl M; Rennert J; Müller-Wille R; Nießen C; Kirchner G; Scherer MN; Schreyer AG; Stroszczynski C; Fellner C; Wiggermann P
    Eur J Radiol; 2013 Oct; 82(10):1710-5. PubMed ID: 23806531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans.
    Nakamura Y; Date S; Toyota N; Tani C; Honda Y; Komoto D; Tanitame K; Awai K
    J Comput Assist Tomogr; 2011; 35(3):351-2. PubMed ID: 21586929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of the transitional phase at gadoxetate disodium-enhanced hepatic MRI for the diagnosis of hepatocellular carcinoma: preliminary results.
    Nakamura Y; Toyota N; Date S; Oda S; Namimoto T; Yamashita Y; Beppu T; Awai K
    J Comput Assist Tomogr; 2011; 35(6):723-7. PubMed ID: 22082543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease: the role of laboratory factors.
    Chernyak V; Kim J; Rozenblit AM; Mazzoriol F; Ricci Z
    J Magn Reson Imaging; 2011 Aug; 34(2):301-9. PubMed ID: 21608069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
    Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
    AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers.
    Tamada T; Ito K; Higaki A; Yoshida K; Kanki A; Sato T; Higashi H; Sone T
    Eur J Radiol; 2011 Dec; 80(3):e311-6. PubMed ID: 21315529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic parenchymal enhancement at Gd-EOB-DTPA-enhanced MR imaging: correlation with morphological grading of severity in cirrhosis and chronic hepatitis.
    Kanki A; Tamada T; Higaki A; Noda Y; Tanimoto D; Sato T; Higashi H; Ito K
    Magn Reson Imaging; 2012 Apr; 30(3):356-60. PubMed ID: 22227353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla.
    Verloh N; Haimerl M; Zeman F; Schlabeck M; Barreiros A; Loss M; Schreyer AG; Stroszczynski C; Fellner C; Wiggermann P
    Eur Radiol; 2014 May; 24(5):1013-9. PubMed ID: 24531844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
    Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
    Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.